August J Moretti
CIK 1344412 · Chief Financial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DEPO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MOUNTAIN VIEW, CA 94043
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VANI | Director | — | $1.16 | — | $0 | 1 | 2026-06-26 |
| CBUS | Director | — | $1.38 | — | $0 | 3 | 2026-06-04 |
| FDMT | Chief Financial Officer | 11,045 | $11.70 | $129.2K | $0 | 7 | 2023-05-16 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Chief Financial Officer & SVP | 74,447 | — | — | -$681.1K | 21 | 2018-04-03 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | SVP, CFO, GC & Sec | 9,942 | — | — | -$382.7K | 27 | 2011-08-01 |
Recent Filings · Page 5 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-12-21 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −14,000 | -$31.2K | EDGAR |
| 2009-12-18 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −14,009 | -$31.2K | EDGAR |
| 2009-11-02 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2009-05-01 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2009-02-26 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Grant (A) | +24,419 | $0 | EDGAR |
| 2009-01-26 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-11-04 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2008-07-11 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-01 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2008-04-02 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Mixed | — | -$29.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.